An investigation for investors in Dr. Reddy’s Laboratories Limited (NYSE: RDY) shares over potential securities laws violations by Dr. Reddy’s Laboratories was announced.
San Diego, CA -- (SBWIRE) -- 08/10/2018 -- An investigation was announced on behalf of investors of Dr. Reddy's Laboratories Limited (NYSE: RDY) shares over potential securities laws violations by Dr. Reddy's Laboratories
Investors who purchased shares of Dr. Reddy's Laboratories Limited (NYSE: RDY), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dr. Reddy's Laboratories Limited (NYSE: RDY) concerning whether a series of statements by Dr. Reddy's Laboratories regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On June 15, 2018, the U.S. District Court for the District of New Jersey granted a request by Indivior PLC ("Indivior") for a temporary restraining order compelling Dr. Reddy's Laboratories Limited's to cease its launch activities related to the Company's Suboxone Film product, pending resolution of Indivior's motion for a preliminary injunction to block the product's release.
On July 13, 2018, the court granted Indivior's motion and entered a preliminary injunction order to that effect.
Those who purchased shares of Dr. Reddy's Laboratories Limited (NYSE: RDY) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels